Cadent Therapeutics and its ion channel programs to be acquired by Novartis

BY      |     December 17, 2020

Cadent Therapeutics, a biopharmaceutical company developing novel treatments for patients with movement and cognitive disorders, announced that it has entered an agreement to be acquired by Novartis. The transaction is expected to close in the first quarter of 2021.

Under the deal, Cadent Therapeutics will receive a $210 million upfront payment and will be eligible for up to $560 million in milestone payments.

The acquisition will give Novartis full rights to Cadent’s neuroscience portfolio, including two NMDAR and one SK channel clinical programs:

  • the Phase I schizophrenia program, CAD-9303 (NMDAR positive allosteric modulator);
  • the Phase II depression program, CAD-9271/MIJ-821 (NMDAR negative allosteric modulator);
  • the Phase II movement disorder program, CAD-1883 (SK channel positive allosteric modulator).

Read the press release here.

Read more about Cadent Therapeutics here.

Read more about Novartis here.

Photo by Oleg Magni from Pexels

Comments? Questions? Suggestions?

If you have any comments, questions or suggestions concerning this article, feel free to email me at
Alternatively, you can leave your comments on LinkedIn or Twitter.